KYMR·Kymera Therapeutics Inc.
KYMR|Analyst Targets
KYMR|Insider Trading
KYMR|Fundamentals
KYMR|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $-1.26 | - | - |
| Q3'25 | $-0.78 | $-0.94 | -20.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3M | - | - |
| Q3'25 | - | $3M | - |
KYMR|Monthly Returns
Market Data
KYMR Stock Snapshot
- Market cap
- 9.01B
- Day range
- $103.45 – $108.65
- News sentiment
- 73/100 · Bullish
- Analyst target
- $139.32 (+28.9%)
- Consensus
- Buy · 32 analysts
The chart on KYMR has not stabilised: price is in the upper part of its 52-week range and the trend is still down. Company-specific news dominates here; sector-level flows matter less than for larger names.
Behaviour On Record
What KYMR's own history says about today's numbers
- Realized volatility (21d)
- 35.1% 3rd pct
- Below its peak
- -14.8%
- vs 200-day average
- +18.0%
- Up days (1y)
- 51%
Kymera Therapeutics Inc. is currently running 35.1% annualised volatility over the last 21 sessions. Measured against KYMR's own 6 years of daily returns rather than a market-wide average, that is the 3rd percentile — unusually subdued by its own history, against a typical reading of 64.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
KYMR is trading -14.8% below its running peak. Across 5 full years on file, its median worst-drawdown-in-a-year was -63.6%, and the deepest was -78.7% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +18.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 61st percentile — a somewhat wider gap than its own norm. Over the past year KYMR closed higher on 51% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 6 years of records, KYMR finished the month higher 3 of 6 times, with a median return of +6.1% and an average of +10.8%. Its strongest month historically has been November at +18.0% on average, its weakest May at -11.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: KYMR has opened more than 2% away from the prior close in 262 of 1,536 sessions (17.1% of the time), with the largest gaps running +23.0% and -12.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 1,537 daily closes between 2020-08-21 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against KYMR's own 6-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of KYMR's sector?
Kymera Therapeutics Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Biotechnology industry group, KYMR ranks 9th of 15 tracked industries, lagging.
- Sector rank
- #3 of 12
- Sector state
- Lagging
- Sector rotation score
- 73
- Industry rank
- #9 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on KYMR?
Citigroup most recently reiterated its rating on Kymera Therapeutics Inc. to Buy on Oct 5, 2026 with a price target of $150 (from $135). Over the last 90 days, coverage has run 1 upgrade against 1 downgrade, a net mixed lean.
- Latest action
- Citigroup — Buy
- 90-day upgrades
- 1
- 90-day downgrades
- 1
- Net rating momentum
- 0
Held by These ETFs
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Citadel Advisors LLC | • Hold | 174,955 | 0.21% | $20.06M | 2026-09-02 |